immunotherapy

Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting

Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy...

GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene...

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria...

Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer

TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada is pleased to award $68,000...

AI In Life Science Analytics Market Size to reach $3.6 billion, Globally, by 2030 – Exclusive Research by The Research Insights

CHICAGO, May 15, 2025 /PRNewswire/ -- The global AI In Life science Analytics Market is projected to be valued at USD 1.9...

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher...

error: Content is protected !!